Business Combination - Pro Forma Information (Details) - Pharmagesic - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Business Combination | ||
| Net loss before taxes | $ (19,649) | $ (11,388) |
| Nonrecurring pro forma transaction costs | 4,900 | $ 0 |
| Success fees | $ 3,600 | |
| X | ||||||||||
- Definition Amount of non-recurring adjustment made for the success fees paid to financial advisors which is directly attributable to business combinations during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of non-recurring adjustment made for the pro-forma transaction costs incurred which is directly attributable to business combinations during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|